Malaria Solution Overview

Malaria Solution Overview

Every 30 seconds, a child dies from Malaria. The disease causes more than 300 million acute illnesses each year, and of those, at least one million die. Nine out of ten of these deaths occur in sub-Saharan Africa, predominately among young children and although effective tools exist to identify and treat malaria, only extremely limited number of patients have access to them. This urgently needs to change.

As one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies, Novartis is in an ideal position to become part of the solution. With the integration of corporate citizenship into your values, culture, and strategy, getting involved in the fight against Malaria makes sense. First, you have access to the essentially drugs that are needed to efficiently and effectively treat Malaria. As a major center of excellence for drug discovery and research, you have the needed expertise, technologies, and more importantly, scientific knowledge. Not only that, but you pure size, power, and thus level of influence, allows you to bring various organizations together to provide better solutions on a unified front. The powerful relationships that you have formed over the years could prove to be especially valuable in leveraging additional partnerships and collaborations with governments, NGOs, and other participants needed in the fight against Malaria.

It's important to understand that we aren't asking for a handout. Studies have shown that consumers in emerging markets are brand loyal and by being a first presence in these areas we will be able to build invaluable brand reputation with future consumers of our products. Emerging markets will provide growth opportunity in providing pharmaceuticals, over the counter drugs, generics, vaccines and animal health drugs to these consumers. Additionally, as a leader